靶向肿瘤微环境的CAR-T治疗研究  

CAR-T Therapy Targeting Tumor Microenvironment

作　　者：肖雪筠 唐奇[2] 新华·那比[1] XIAO Xue-jun;TANG Qi;XINHUA Nabi(Department of Pharmacology,Xinjiang Medical University,Urumqi 830000,China;National Health Commission Key Laboratory of Antibody Technique,Naning Medical University,Nanjing 210029,China)

机构地区：[1]新疆医科大学药学院,乌鲁木齐830000 [2]南京医科大学国家卫计委抗体技术重点实验室,南京210029

出　　处：《中国生物工程杂志》2020年第12期67-74,共8页China Biotechnology

基　　金：新疆维吾尔自治区高校科研计划(XJEDU2020I012)资助项目。

摘　　要：癌症仍然是现阶段威胁人类健康的一大难题,随着医学的发展,癌症治疗方法除传统方法:手术、放疗、化疗,还可以采用免疫疗法。目前,癌症免疫疗法受到广泛关注,但在应用方面具有许多局限性,如PD-1/PD-L1抑制剂,在应用的过程中会出现获得性耐药现象,因此细胞免疫疗法(chimeric antigen receptor T cell,CAR-T)应运而生,成为弥补免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)和单克隆抗体药物缺陷的新兴治疗方式,简要介绍了CAR-T免疫疗法的产生、应用及对TME相关靶点的研究进展,为后续研究提供一定的思路。Cancer is still a major problem threatening human health in recent years.With the development of medicine, besides the traditional methods of cancer treatment: surgery, radiotherapy, chemotherapy,immunotherapy can also be used.At present,cancer immunotherapy has been widely concerned,but there are many limitations in its application.For example,PD-1/PD-L1 inhibitors are found to have acquired drug resistance in the process of application.Therefore,cellular immunotherapy( chimeric antigen receptor T cell,CAR-T) emerges as the times require,becoming a new treatment method to make up for the defects of immune checkpoint inhibitors( ICIs) and monoclonal antibody drugs.Through briefly introduces the emergence and application of CAR-T immunity therapy and the research progress on TME related targets,providing certain ideas for the follow-up research.

关 键 词：肿瘤 靶向药物 CAR-T 肿瘤微环境 

分 类 号：Q819[生物学—生物工程]